1. Poland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Synektik SA

Synektik SA

GGPW:SNT
336.00
PLN
-12.60
(-3.61%)
20.81EPS
6.80P/E
2.84BMarket Cap
Dec 02Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.53
11.56
9.16
9.8
5.8
12.35
15.8
14.7
15.08
19.56
52.39
73.18
79.91
109.38
Basic EPS, GAAP
-0.1
1.15
0.36
-0.15
0.05
1.21
1.07
1.03
0.98
1.21
6.15
9.68
12.07
48.95
Free Cash Flow per Basic Share
-0.08
-2.14
-0.37
-0.57
-1.76
0.33
0.94
1.03
2.14
-1.92
10.13
5.25
7.14
18.18
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.36
0.45
0.45
0.6
3.03
8.25
- -
Book Value per Share
2.64
8.17
6.78
6.63
6.68
7.27
8.24
8.91
9.45
10.3
15.73
22.28
26.21
25.11
Tangible Book Value per Share
2.24
7.71
5.49
4.12
3.31
4.5
5.25
5.68
6.1
3.66
9.83
17.33
21.57
20.92
Basic Weighted Avg Shares
6
7
9
9
9
9
9
9
9
9
9
9
9
9
Sales/Revenue/Turnover
61
77
78
84
49
105
135
125
129
167
447
624
682
933
Operating Margin (%)
0.26
13.31
6.3
-0.67
3.94
2.73
9.53
10.14
8.82
6.85
15.81
20.59
23.47
24.16
Depreciation Expense
3
3
4
4
2
7
5
7
8
12
15
17
21
21
Net Income, GAAP
-1
8
3
-1
- -
10
9
9
8
10
52
83
103
417
Effective Tax Rate (%)
- -
16.46
26.34
- -
80.11
3.91
22.36
20.58
17.98
16.17
20.13
20.13
19.32
19.21
Profit Margin (%)
-1.05
9.94
3.95
-1.51
0.79
9.77
6.78
7.03
6.52
6.17
11.74
13.23
15.1
44.75
Working Capital
4
25
19
6
4
-2
6
12
9
5
50
78
131
124
LT Debt
6
8
8
4
3
11
9
15
12
13
14
19
26
31
Total Equity
18
55
58
57
57
62
70
76
81
88
134
190
224
214
Return on Invested Capital (%)
- -
18.3
5.1
- -
0.66
15.81
12.27
10.63
9.34
13.11
37.69
52.86
51.34
73.66
Return on Capital (%)
- -
18.77
5.48
- -
0.7
15.64
12.06
10.4
8.99
10.31
38.88
45.57
43.78
176.02
Return on Common Equity (%)
-3.58
21.2
5.47
-2.21
0.68
17.31
13.82
12.05
10.71
12.23
47.24
50.93
49.78
205.88

Capital Structure

PLN

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
9
32
10
LT Borrowings
7
7
11
LT Finance Leases
16
18
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
2,140
2,220
2,840

Working Capital

PLN

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
446
319
392
Cash, Cash Equivalents & STI
166
37
79
Accounts Receivable, Net
155
200
246
Inventories
98
73
59
Total Current Liabilities
285
260
268
Payables & Accruals
- -
- -
- -
ST Debt
9
32
10
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.59%
25.41%
17.64%
Free Cash Flow
-38.53%
-144.29%
36.02%
Net Income, GAAP
277.51%
101.86%
24.66%
Sales/Revenue/Turnover
34.93%
49.8%
9.21%
Total Cash Common Dividend
- -
- -
172.28%

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
271
88
124
141
624
2025
203
125
154
199
682
2026
228
213
292
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.06
1.43
1.96
2.22
9.68
2025
3.88
2.58
2.78
3.63
12.07
2026
4.1
34.75
6.46
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.03
2025
- -
- -
10.75
- -
8.25
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cezary Dariusz Kozanecki
Full Time Employees
239
Sector
Health technology
Industry
Medical specialties
Address
ul. Józefa Piusa Dziekonskiego 3 Warsaw MZ Poland 00-728
IPO Date
Aug 9, 2011
Website
synektik.com.pl
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Synektik Spólka Akcyjna is a leading Polish company specializing in the production and provision of advanced medical technologies primarily for surgery, diagnostic imaging, and nuclear medicine. Its core products include medical devices such as the Da Vinci robotic surgical systems, diagnostic imaging equipment, and IT solutions like PACS (ARPACS) software for image registration, visualization, description, and archiving. Synektik also produces radiopharmaceuticals used in cancer diagnosis (PET), operates a research laboratory for acceptance and specialized testing of X-ray equipment, and offers maintenance services for medical imaging equipment. Founded in 1992 and headquartered in Warsaw, Poland, Synektik primarily serves the Polish healthcare market but has expanding operations and technology transfers to the United States and neighboring Baltic countries. Recent major developments include signing a significant contract worth 15.7 million PLN with the State Medical Institute MSWiA for Da Vinci robotic surgery systems, aiming to sell more than 30 units in the 2025/2026 fiscal year. Synektik has also completed the transfer of technology for producing cardioneutral diagnostic radiopharmaceuticals to US centers, with plans to apply for FDA approval to start phase III clinical trials in 2026. The company’s financial health improved markedly, reporting a 61% year-over-year EBITDA increase to 54.6 million PLN in Q4 2024/25 with net profit of 30.9 million PLN, driven by growth in medical equipment sales and recurring revenue streams. Synektik operates through segments focused on medical device sales, IT solutions, equipment maintenance, and radiopharmaceutical production, maintaining key strategic partnerships such as with Siemens. Synektik’s recent strategic shifts emphasize expanding its robotic surgery footprint, advancing regulatory approvals for novel radiopharmaceuticals, and increasing export sales to the Baltic states, marking significant growth and internationalization in its business profile. Its headquarters remain in Warsaw, Poland, with operations that effectively blend product innovation, service provision, and technology transfer activities.